TruScreen Investor Presentation

Investor
Presentation
May 2025
Not for distribution or release in the United States

2
Disclaimer and important notice
This presentation has been prepared by TruScreen Group Limited (TRU). This presentation has been prepared in relation to the offer of new shares in TRU (New Shares) by way of a:
•Placement to selected investors in certain jurisdictions (Placement); and
•Share Purchase Plan to TRU's eligible existing shareholders with an address in either New Zealand or Australia (SPP),
under clause 19 of Schedule 1 of the Financial Markets Conduct Act 2013 (FMCA) in New Zealand and in accordance with the relief granted in Australian Securities and Investments Commission (ASIC) Instrument 23-
0122 and ASIC Corporations (Share and Interest Purchase Plans) Instrument 2019/547 as amended by ASIC Instrument 25-0323 in Australia (together, the Offer).
Information of a general nature:
This presentation contains summary information about TRU and its activities which is current as at the date of this presentation. The information in this presentation is of a general nature and does not purport to be
complete nor does it contain all the information which a prospective investor may require in evaluating a possible investment in TRU or that would be required in a product disclosure statement for the purposes of the
FMCA or a prospectus or other disclosure document for the purposes of Chapter 6D of the Australian Corporations Act 2001 (Cth) ("Australian Corporations Act"). The historical information in this presentation is, or is
based upon, information that has been released to NZX Limited (NZX) and ASX Limited (ASX). This presentation should be read in conjunction with TRU’s other periodic and continuous disclosure announcements,
which are available at www.nzx.com and www.asx.com.au.
NZX and ASX:
The New Shares will be quoted on the NZX Main Board following completion of each of the Placement and the Retail Offer, and an application will be made by TRU for the New Shares to be quoted on the ASX.
Neither NZX nor ASX accepts any responsibility for any statement in this presentation. NZX is a licensed market operator, and the NZX Main Board is a licensed market under the FMCA.
Not financial product advice:
This presentation is for information purposes only and is not financial, investment or financial product advice or a recommendation to acquire TRU securities and has been prepared without taking into account the
objectives, financial situation or needs of individuals. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own objectives,
financial situation and needs and consult a broker, solicitor, accountant and/or other professional adviser.
Past performance:
Past performance information given in this presentation is given for illustrative purposes only and should not be relied upon as (and is not) an indication of future performance.
Future performance:
This presentation contains certain "forward-looking statements" such as indications of, and guidance on, future earnings and financial position and performance. Forward-looking statements can generally be
identified by the use of forward-looking words such as ‘projected, 'expect', 'anticipate', 'likely', 'intend', 'could', 'may', 'predict', 'plan', 'propose', 'believe', 'forecast', 'estimate', 'target', 'outlook', 'guidance' and other similar
expressions within the meaning of securities laws of applicable jurisdictions, and include, but are not limited to future revenues, the timing of implementation of certain initiatives, growth strategies, the timetable of
the Offer and the use of proceeds. The forward-looking statements contained in this presentation are not guarantees or predictions of future performance and involve known and unknown risks and uncertainties and
other factors, many of which are beyond the control of TRU, and may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct. There can be no
assurance that actual outcomes will not materially differ from these forward-looking statements. A number of important factors could cause actual results or performance to differ materially from the forward-looking
statements, including the risk factors set out in this presentation. Investors should consider the forward-looking statements contained in this presentation in light of those disclosures.

3
Disclaimer and important notice (continued)
Future performance (continued):
The forward-looking statements are based on information available to TRU as at the date of this presentation. Except as required by law or regulation (including the NZX and ASX Listing Rules) TRU undertakes no
obligation to provide any additional or updated information whether as a result of new information, future events or results or otherwise. Indications of, and guidance on, future earnings or financial position or
performance are also forward-looking statements. An investment in securities in TRU is subject to investment and other known and unknown risks, some of which are beyond the control of TRU. TRU does not
guarantee any particular rate of return or the performance of TRU.
Financial data:
All dollar values are in New Zealand dollars (NZ$ or NZD) unless otherwise stated.
Investors should be aware that this presentation contains certain financial information and measures that are "non-GAAP financial information" under the New Zealand Financial Markets Authority Guidance Note on
disclosing non-GAAP financial information, "non-IFRS financial information" under Regulatory Guide 230 on disclosing non-IFRS financial information published by ASIC and "non-GAAP financial measures" within the
meaning of Regulation G, under the U.S. Securities Exchange Act of 1934, and, therefore, are not recognised under New Zealand equivalents to International Financial Reporting Standards (NZ IFRS) and International
Financial Reporting Standards (IFRS). The disclosure of such non-IFRS/GAAP financial information and financial measures in the manner included in this Presentation would not be permissible in a registration
statement under the U.S. Securities Act of 1933 (the U.S. Securities Act). The non-IFRS/non-GAAP financial information and financial measures do not have a standardised meaning prescribed by NZ IFRS, Australian
Accounting Standards or IFRS, and therefore, may not be comparable to similarly titled measures presented by other entities, nor should they be construed as an alternative to other financial measures determined in
accordance with NZ IFRS or IFRS. Although TRU believes the non-IFRS/non-GAAP financial information and financial measures provide useful information to users in measuring the financial performance and
condition of TRU, investors are cautioned not to place undue reliance on any non-IFRS/non-GAAP financial information or financial measures included in this presentation.
Pro forma financial information:
This presentation also contains pro forma historical financial information to show the impact of the Placement. The pro forma information has not been audited or reviewed by TRU's auditors. The pro forma financial
information provided in this presentation is for illustrative purposes only and is not represented as being indicative of TRU's views on its future financial condition and/or performance. The pro forma financial
information has been prepared on the basis set out in this presentation. Investors should note that the pro forma financial information has not been prepared in accordance with, and does not purport to comply with,
Article 11 of Regulation S-X under the U.S. Securities Act.
Not a registered offer document:
This presentation is not a product disclosure statement, prospectus or other disclosure document under New Zealand law, Australian law, or any other law (and will not be lodged with the Registrar of Financial
Service Providers, New Zealand Companies Office, ASIC or any other regulator or exchange in New Zealand, Australia or any other jurisdiction). Such regulators take no responsibility for the contents of this
presentation. Accordingly, this presentation may not contain all information which a prospective investor may require to make a decision whether to subscribe for New Shares and it does not contain all of the
information which would otherwise be required by New Zealand law, Australian law or any other law to be disclosed in a regulated product disclosure statement, prospectus, or any other form of disclosure document.
This presentation is for information purposes only and is not an invitation or offer of securities for subscription, purchase or sale in any jurisdiction, including the United States (and will not be lodged with the U.S.
Securities Exchange Commission).
Any decision to purchase New Shares in the SPP should be made on the basis of the information to be contained in a separate offer document to be prepared and made available to eligible retail shareholders. The
offer booklet for the SPP will be available to eligible retail shareholders in New Zealand and Australia following its lodgement with NZX and ASX. Any eligible shareholder who wishes to apply for New Shares under the
SPP should review the offer booklet and apply in accordance with the instructions contained in the offer booklet or as otherwise communicated by TRU. This presentation does not constitute investment or financial
advice (nor tax, accounting or legal advice) or any recommendation to acquire New Shares and does not and will not form any part of any contract for the acquisition of New Shares. The release, publication or
distribution of this presentation (including an electronic copy) in jurisdictions outside New Zealand and Australia may be restricted by law and you should observe such restrictions and should seek your own advice
on such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable securities laws (see the Foreign Selling Restrictions section of this presentation).
By attending or reading this presentation you represent, warrant and agree that you: (i) are entitled to and permitted under applicable laws and regulations to receive the information contained in this presentation in
accordance with the restrictions as set out in this section of the presentation; (ii) will base any investment decisions solely on information released by TRU via NZX and ASX (including, in the case of the SPP, the offer
booklet for the SPP), and (iii) agree to be bound by the limitations contained therein.

4
Disclaimer and important notice (continued)
Distribution of presentation:
This presentation (including an electronic copy) must not be distributed in any jurisdiction to the extent that its distribution in that jurisdiction is restricted or prohibited by law or would constitute a breach by TRU of
any law. The distribution of this presentation in other jurisdictions outside New Zealand or Australia may be restricted by law, and persons into whose possession this presentation comes should observe any such
restrictions. Any failure to comply with such restrictions may violate applicable securities laws. None of TRU, any person named in this presentation or any of their affiliates accept or shall have any liability to any
person in relation to the distribution or possession of this presentation from or in any jurisdiction.
Not for distribution or release in the United States:
This presentation may not be released or distributed in the United States. This presentation does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States or any other
jurisdiction in which such an offer would be illegal. The offer and sale of the New Shares have not been, and will not be, registered under the U.S. Securities Act or the securities laws of any state or other jurisdiction of
the United States. Accordingly, the New Shares may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration requirements of the U.S. Securities Act and any
other applicable securities laws of any state or other jurisdiction of the United States.
Eligibility:
Determination of eligibility of investors for the purposes of the Offer (or any part of the Offer) is determined by reference to a number of matters, including legal and regulatory requirements, logistical and registry
constraints and the discretion of the underwriters and lead managers, and TRU. Each of the underwriters and lead managers and TRU and each of their respective related bodies corporate and affiliates, and each of
their respective directors, officers, partners, employees, representatives and agents, disclaim any duty or liability in respect of that determination and the exercise or otherwise of that discretion, to the maximum
extent permitted by law.
Disclaimer:
To the maximum extent permitted by law, the lead managers, TRU, and their respective advisers, affiliates, related bodies corporate, directors, officers, partners, employees and agents exclude and disclaim all
liability, for any direct or indirect expenses, losses, damages or costs incurred by you as a result of your participation in the Offer and/or the information in this presentation being inaccurate or incomplete in any way
for any reason, whether in tort (including negligence), arising under statute, in contract or equity or otherwise. To the maximum extent permitted by law, the underwriters and lead managers and their respective
advisers, affiliates, related bodies corporate, directors, officers, partners, employees and agents (Specified Persons) make no representation or warranty, express or implied, as to the currency, accuracy, reliability or
completeness of information in this presentation and, with regards to each Specified Person, take no responsibility for any part of this presentation or the Offer. The Specified Persons make no recommendations as to
whether you or your related parties should participate in the Offer nor do they make any representations or warranties to you concerning the Offer, and you represent, warrant and agree that you have not relied on any
statements made by any of the Specified Persons in relation to the Offer and you further expressly disclaim that you are in a fiduciary relationship with any of them. You agree that you will not bring any proceedings
against or hold or purport to hold any Specified Person liable in respect of this presentation or the information in this presentation and waive any rights you may otherwise have in this respect. Statements made in this
presentation are made only as the date of this presentation. The information in this presentation remains subject to change without notice. TRU reserves the right to withdraw the Offer or vary the timetable for the
Offer (whether for the Placement or the SPP) without notice.
General:
For the purposes of this Disclaimer and Important Notice, "presentation" means the slides, any oral presentation of the slides by TRU, any question-and-answer session that follows that oral presentation, hard copies
of this presentation and any materials distributed at, or in connection with, that presentation.

Who is TruScreen
The TruScreen Technology
Why TruScreen
TruScreen Sales Strategy and Markets
TruScreen Highlights CY 24 – CY25
TruScreen Outlook: FY26 and Beyond
TruScreen Options Key Terms

6
Who is TruScreen
Dual listed on the Australian (ASX) (foreign exempt listing) and New Zealand (NZX) stock
exchanges, with a common ticker code of TRU.
TruScreen Group Ltd is a revenue generating Life Science company with FY25 annual
sales of NZ$ 1.7m, down from $2.1m in FY24. This lower result was largely due to delays in
programs in Zimbabwe (delayed until FY26), Vietnam (launched April 2025), and delayed
product registrations in Indonesia and Uzbekistan. Sales from these delayed commercial
activities are expected to be realised in FY26.
TruScreen Group Ltd expects FY26 sales to exceed NZ$ 2.8m

7
Market Cap:
NZ $16.09M
Share Price:
AU$0.027 / NZ$0.029
Cash Balance (pro-forma):
NZ$365,000
Issued Capital: 554,907,719
Current Holders: 1942
Key FinancialsTRU Price History (NZX)
As at 28 May 2025

8
An Experienced Leadership Team
•Currently a Director and Chairman of a number of listed ASX
companies.
•Previous Executive Director of sales and distribution company
Arthur Yates & Co Limited, as well as Finance Director/CFO of
listed retailers on the ASX – M. S. McLeod Holdings Limited
(Downtown Duty Free), Galore Group Limited (Barbeques Galore)
and Brazin Limited (Bras N Things, Sanity Music).
•Prior to joining commerce, Tony was a partner of Cox Johnston &
Co, Chartered Accountants which has since merged with Ernst &
Young.
•Involved with TruScreen for a number of years. He is an experienced business
executive and has acted in a number of management roles including 20 years as a
senior partner of KPMG and its predecessor firms.
•Director of a number of private companies across a broad range of business activities
including corporate advisory, financial services, and funds management.
•Commerce graduate from the University of New South Wales, Sydney, Australia and a
Fellow of the Institute of Chartered Accountants in Australia and New Zealand. Chris is
also the Chair of TruScreen’s Audit, Finance and Risk Committee.
Mr. Anthony Ho
B. Com (UNSW), CA, FAICD,
FCIS, FGIA
Non-executive Chairman
Mr. Christopher Horn
B. Com (UNSW), FCA
Non-executive Independent Director

9
An Experienced Leadership Team
•MBA from the Macquarie Graduate School of Management,
and Bachelor of Nursing from the Auckland Technical
Institute.
•More than 20 years’ experience working in Asia and Pacific
markets in Healthcare, in sales, Marketing and leadership.
Juliet was the General Manager/Country Director for Johnson
& Johnson Medical in New Zealand and has held various roles
in Johnson & Johnson in Australia and New Zealand since
2012.
•Experienced medical device engineer and specialist in product research and
development. Research and Development Manager of the respiratory
humidification division of Fisher & Paykel Healthcare, an ASX/NZX listed
healthcare company.
•20 Years of experience, Dr. Cheung brings a strong understanding of
manufacturing processes and has worked with suppliers and manufacturers
across the glove.
•Technical background in opto-electronics and expertise in medical device
engineering is highly relevant to TruScreen, who’s cervical cancer screening
device harnesses opto-electronic signatures for screening results.
Ms. Juliet Hull
B.Nurse ATI, MBA MGSM
Non-executive Director
Dr. Dexter Cheung
B. Tech (Hons), M.Eng, PHD
Non-executive Director

10
An Experienced Leadership Team
Mr. Guy Robertson
B. Com (Hons.) CA
CFO & Company
Secretary
Professor Michael
Campion
Medical Advisory
Committee Chair
•Martin Dillon, the CEO of TruScreen Group Ltd,
skilfully managed the company’s listing on the
NZX and oversees its strategic vision. With over
30 years of commercial experience, he has
engaged with health and regulatory authorities
worldwide.
•Martin has held senior executive roles including
at CEO and Managing Director level in private and
public companies in healthcare, advertising and
marketing.
Martin Dillon
CEO
•Guy is an experienced finance executive, having held
the positions of Director, Company Secretary and
Chief Financial Officer of both private and ASX-listed
companies in Australia and Hong Kong.
•Guy held senior roles in the Jardine Matheson Group
of Companies, including General Manager Finance of
Franklins Limited, Chief Operating Officer of Colliers
International Asia Pacific and Managing Director
(NSW) Jardine Lloyd Thompson.
•University of New South Wales graduate (1977),
Scientific Program Director of the British Society for
Colposcopy and Cervical Pathology (1985 - 1987).
•Victor Bonney Award recipient (London Obstetrics and
Gynaecology Society, 1986) for his pivotal research into
the role of human papillomaviruses in the causation of
cervical cancer.
•Director of the Preinvasive Unit, Gynaecological Cancer
Centre, Royal Hospital for Women, Randwick
•Published over 60 academic papers, articles, book and
book chapters and presented at numerous scientific
congresses.

11
2025 & BeyondBuilding for the Future 2020-2024
Building the Fundamentals 2014 - 2020
The TruScreen Journey
China Growth continues
Distribution of Dalton Bio IVD HPV DNA products
Vietnam HPHA program targets 260,000 women,
Uzbekistan and Zimbabwe screening programs to
commence.
Indonesia and ASEAN commence commercial use
Global focus on AI boosts recognition of TruScreen
523% sales
growth in H1
2018 Oct
Recognition by
World Health
Organization
2019 May
2020 Jan
ASX Listing
2014 Nov
Listing on NZAX
2023-24
COGA Blue Book and CSCCP Guidelines include TruScreen
UNITAID recognises TruScreen’s value for Cervical Cancer screening
WHO invited TruScreen to participate in Key AI meeting for cervical cancer
screening
Vietnam – HPHA large scale screening MOU signed
2018 Jul
Comence large
scale pilot
programs in China
with CDC and COG
2018 Dec
Migration to NZX
2022
Managing COVID-19 challenges
Cost reduction
Manufacturing and business
development in China
Completion of major COGA study
Strengthen distributor
arrangement in Vietnam
CFDA (NMPA)
approval for second
generation device
2017 Dec

The TruScreen
Technology

13
Handheld device (HHD)
Intelligent Cradle
Single Use Sensor (SUS)
•Enabled by AI, TruScreen provides an accurate, real time cervical cancer screening solution
•Each TruScreen examination takes one to two minutes to produce results, compared to
conventional Pap tests which can take days, weeks, or even months in some countries, for a
result to be returned.

14
a pen-like wand covered by a
Single Use Sensor (SUS) is used
to gently touch multiple spots on
the cervix. The SUS contains a
precision lens and electrodes
which interfaces with the cervix.
It sends and picks up low level
electrical and optical signals (14
readings per second) from the
cervical tissue.
1
How it works

15
The TruScreen Handheld Device (HHD) then applies
an integrated AI-enabled algorithm to analyse these
signals and compares them to an integrated
database of 2,000 patients drawn from a wide range
of geographic and ethnic backgrounds with differing
histological diagnoses.
This identifies the presence of abnormal (cancerous
and pre-cancerous) cells in the cervix and provides
physicians with real-time results.
2
How it works

16
✓Clinicians/physicians are able to immediately plan
appropriate patient care
✓Device has an expected life span of 5–7 years
✓Disposable SUS is used once per test per patient - ensures
there is no chance of cross-infection between patients
✓The entire patient data collection and analysis is self-
checked and controlled. No tissue sample needs to be
taken. These measures ensure that the results are reliable
and consistent, and that the examination is painless and
safe
✓TruScreen has been used on over 1 million women and
there has never been a single adverse event reported

Why TruScreen?

18
Extensive body of clinical evidence
Over 40,000 women in clinical trials to date***
***Total number of subjects across published and unpublished clinical studies in English, data from TruScreen device generation I and II
YearCountryInvestigatorN
2002ChinaDr Huang Yi683
2002ChinaDr Wang Ziyao301
2003UK/Aus Prof A. Singer651
2008Poland Dr. Pruski234
2009ChinaProf Ding Ma302
2010ChinaDr. He Xiu-Kui392
2010ChinaProf Fengnian Rong532
2010Korea Dr. Hyeong Soo Lim292
2011Poland Dr. Pruski293
2011ChinaDr. Li Xia500
2015Turkey Dr. Özgü E285
2016ChinaDr. LI Pei,368
2017Mexico Dr. Ricardo Lua521
2018ChinaDr. Huixia Yang2730
2018-2021China54 Hospitals14,982
YearCountryInvestigatorN
2019ChinaDr. Baojin Wang315
2019ChinaDr. Wei Zhang1030
2019ChinaDr. Yanhong Jia320
2020ChinaDr Kang Yanan192
2021ChinaProf Chen Fei974
2021ChinaDr Wei Yingting458
2022ChinaDr Chen Zhenbo476
2022ChinaDr Zhu Bo283
2022ChinaDr Zhao Yuqian1319
2022AustraliaDr Jessica Vet506
2023ChinaDr Luo Lianmei318
2023ChinaDr Liu Hang997
2024ChinaDr Yang Yueming489
2024ChinaDr Fengyi Xiao & Long Sui1908
2024Saudi ArabiaDr S Maqsood and DrM Alhudhud507

19
•TruScreen specificity surpassed Liquid Based Cytology (LBC) and hrHPV
•TruScreen was determined to be a simple, effective and rapid real-time cervical cancer screening method
•TruScreen was determined to be an appropriate primary cervical cancer screening tool in regions with high morbidity and mortality
to cervical cancer
•Also highlighted the superiority of TruScreen against alternative screening methods as well as the potential benefits of a TruScreen-
HPV co-testing. The size of the COGA study, which was TruScreen’s largest clinical evaluation to date, lends extra significance to its results and
broad conclusions.
TruScreen’s
sensitivity
was well above that for LBC
(87.5% v’s 66.5%), with a high
degree of statistical
significance (p<0.001).
TruScreen’s
specificity
(88.4%) was higher than both
LBC (86.3%) and hrHPV
testing (78.3%) (also at
p<0.001).
The sensitivity of TruScreen-hrHPV co-
testing (carrying out with multiple types
of screening tests at the same time, as
opposed to a single type) was higher than
that of LBC-hrHPV co-testing,
98.4% vs 95.9%
(statistically significant at p=0.006).
COGA Trial (n= 15,661, 2018-2021)

4

20
Why TruScreen?
TruscreenLiquid Based Cytology (LBC)HPV DNA
Real time results
Low infrastructure
costs
Strong clinical results
Objective results
Low training threshold
Portable
No cell or tissue
samples taken

TruScreen Sales Strategy
and Markets

22
TruScreen Sales Strategy
•TruScreen focuses on emerging economies such as China, India, Indonesia, Mexico,
Uzbekistan, Vietnam and Zimbabwe. Unlike the developed western markets, these countries
have no or minimal large-scale cervical cancer screening programs and infrastructure.
•This creates a gap in the market for TruScreen that is not available in the developed market and
allows quicker market access from a relative lack of existing competition.
•In contrast to competing products such as cytology and HPV DNA screening TruScreen is
‘capital light’, not requiring lab infrastructure to be established prior to commencing screening.

23
Recurring Revenue Model
•TruScreen manufactures two devices –
oone made in China for use in China, where locally manufactured products have
preferential market access
oone made in Australia for other markets
•For each patient screened with the TruScreen device a new disposable Single Use Sensor
(SUS) must be used. This creates a recurring revenue model with a consumable sale for
each patient screened with TruScreen.

24
Entry into Public Screening Programs
•TruScreen’s sales to date have been achieved largely through traditional sales of devices and
Single Use Sensors to hospitals and clinics. In FY25 these traditional channels made up 99%
of sales.
•Following the previous success of TruScreen’s use in public screening programs in Zimbabwe,
TruScreen is currently targeting public screening programs in Zimbabwe, Vietnam, Uzbekistan
Mexico and Eswatini.
•These programs have large numbers of enrolled women (e.g Ho Chi Minh City - 260,000 women
to be screened over 5 years) and are expected to contribute greater than 20% of total sales in
FY26.
•An ever increasing percentage of sales is expected from these programs in following years.

25
China
477M
RUSSIA
48M,
CENTRAL ASIA
13M
ASEAN &
INDONESIA
142M
MEXICO
46M
VIETNAM
36M
SAUDI
11M
SOUTHERN
& CENTRAL
AFRICA
134M
INDIA
468M
UZBEKISTAN
12M
TruScreen’s presence and global markets
Existing market
Target market

26
World Health Organisation (WHO)
UNITAID
Clinton Health Access Initiative
Daffodil Foundation - Australia
China Obstetricians and Gynaecologists
Association
China Society for Colposcopy and
Cervical Pathology
Russia Cervical Cancer Screening
Guideline
Vietnam Hospital Technical List
•CE Mark, European Union
•NMPA, China
•TGA, Australia
•MHRA, UK
•SFDA, Saudi Arabia
•Roszdravnadzor, Russia
•COFEPRIS, Mexico
•WAND New Zealand
•Zimbabwe Ministry of Health
•IEAKI Indonesia
•Vietnam Technical List
TruScreen Regulatory Approvals
ISO 13485
ISO 60601-1-2
CE Mark
International Approvals:Recognized by
International Quality
Accreditation:

TruScreen Highlights
CY24 - CY25

28
TruScreen and Dalton BioScience
MOU signed February 2025 between TruScreen Group Ltd and Hangzhou Dalton Bioscience
•TruScreen to distribute globally (excluding USA and Canada) via selected distributors DaltonBio HPV related IVD
products including DNA tests and Self Sampling.
•DaltonBio to explore opportunities to assist TruScreen’s AI enabled real time cervical screening device within its
distribution network, notably its 200 Sub-distributors in China and regulatory and distribution partners in South
America

29
Key market China, accounting for over 85% of global sales,
exceeded budget and is poised for expansion in 6 key provinces
•Key provinces for growth: TruScreen’s China distributor Beijing Siweixiangtai
Technology Co Ltd (SWXT) is targeting 6 key provinces for growth in FY26 - Guangxi,
Jiangsu, Hunan, Zhejiang, Shanghai and Guangdong. These provinces have a
combined population of 496 million, and an addressable screening market of
approximately 124 million women.
•TruScreen unaffected by US and China proposed tariff regimes: TruScreen markets
both an Australian and a Made in China device, providing a dual product strategy in the
key China market, with preferential market access for China manufactured products
•SUS Pull Through: Consumable Single Use Sensor (SUS) pull through per month per
device has reached peak of 142 SUS per month per device, an increase of 30 % over 12
months.
•Software Upgrade: China’s NMPA registration variations have been approved and
software upgrade on Chinese devices has commenced. The upgrade will improve user
experience for clinicians and extend the device’s in-use service interval.
CHINA
477 million
women of
screening age*

30
•Private Sector Expansion: SWXT targeting of the growing China private health
sector including private clinic and Health Check Centre approvals in Jiangsu and
Shenzhen, and entry into the Luxury Hospital and Traditional Chinese Medicine
Hospital sectors.
•Public Health Insurance: In addition to having 11 provinces with approved pricing
for TruScreen, Beijing has awarded public health insurance reimbursement for
eligible TruScreen patients. Shanghai has completed the final round of evaluation
for public health insurance reimbursement and once he administrative processes
for this are formalised sales are expected to grow rapidly in this province.
CHINA
477 million
women of
screening age*
In April 2025 TruScreen and SWXT
planned the expansion of TruScreen
sales in China. From left to right: Mr Li,
partner SWXT, Marty Dillon, CEO
TruScreen, Miss Su Siming, Managing
Director SWXT, Tony Ho, Chair
TruScreen and Mr Wang, SWXT
manager of TruScreen business in
China

31
TruScreen selected to screen 260,000 women in Ho Chi
Minh City and adoption in Vietnam picks up pace
VIETNAM
36 million
women of
screening age*
•The formal agreement to conduct a 5-year program to screen 260,000 women for cervical
cancer in Ho Chi Minh City was signed in April 2025
Following the signing of a Memorandum of Understanding with the Ho Chi Minh City Public Health
Association and Gorton Health Services (Truscreen’s Vietnam distributor) in November, TruScreen
has been selected as the primary screening methodology for the capability of its unique, AI-
enabled real time cervical cancer screening technology to assist the Government of Vietnam
achieve its goal of screening 60% of women aged 30 to 54 for cervical cancer (currently only 25%
screened).
•Public Hospital Adoption
In January 2025 Professor Michael
Campion presented at Tu Duc
Hospital in Ho Chi Minh City,
leading to 6 major Ho Chi Minh City
hospitals agreeing to adopt and
install TruScreen.
April 12 2025. TruScreen Chair Tony
Ho, President of the Ho Chi Minh City
Public Health Association Dr Le
Truong Giang and Managing Director
of Gorton Health Services Mr An
Trang sign the formal agreement to
conduct a 260,000 women screening
program in Ho Chi Minh City.

32
TruScreen re-enters India with appointment of Renovate
Biologicals Pvt Ltd in April 2025
INDIA
468 million
women of
screening age*
India holds one-sixth of the world's population and one woman dies from
cervical cancer every eight minutes in the country.
The cervical cancer screening rate is only 2%, and India’s National
Academy of Medical Sciences (NAMS) has recently set a target of 70% by
2030.
The appointment of Renovate Biologicals now gives TruScreen distribution
capability in 3 of the 4 most populous countries in the world - China, India
and Indonesia.

33
Indonesia product registration completed and distributor
appointed, with commercial activity commenced in May 2025
INDONESIA
96 million
women of
screening age*
•Distributor Appointed: Following the completion of product registration,
TruScreen appointed a new Indonesian medical products distributor PT
Mawar Mitra Medika with commercial sales commenced in the world’s
largest Islamic nation, with a population spread over 14,000 islands.
TruScreen offers an ideal solution to providing screening to a geographically
dispersed and diverse population.
•AI presentation by CEO to MOH officials and KOL’s. In December 2024,
TruScreen presented to an AI Health webinar organised by Austrade and the
Indonesian Ministry of Health. TruScreen was one of only two companies
invited to present at this webinar, a recognition of our growing reputation as
a leader in AI innovative health technology with a particular relevance to
emerging economies.

34
TruScreen results and suitability in emerging markets continues to be validated by
independent studies and the World Health Organization
•October 2024 – UNITAID included TruScreen in its
technology landscape report “Screening and
treatment of pre-cancerous lesions for secondary
prevention of cervical cancer”, the only opto-
electrical device included
•October 2024 - TruScreen selected as a ‘Top 6
Pick’ - one of six global companies, from a cohort
of 580 companies, that will have an impact on
global women’s health. The evaluation was
conducted by Austrian based StartUs Insights.

35
•November 2024 – following the UNITAID inclusion, TruScreen were invited to present at the World Health
Organisation (WHO) key meeting to further the use of AI technologies for screening of cervical cancer in
Edinburgh, and were the only opto-electric tissue differentiating medical device company invited to participate.
•November 2024 - An Obstetrics and Gynaecology Hospital of Fudan University study (n=1908) concluded that
TruScreen optoelectronic real time screening detection accuracy was outperformed liquid-based cytology
(LBC) in patients with type 3 cervical transformation zone. The report was published by leading research
journal, Germany’s Springer Nature
•July 2024/April 2025 - The preliminary publication in July 2024 of a Saudi Arabia study investigating TruScreen’s
performance versus pap smears in cervical cancer detection, was peer reviewed and published by globally
renowned BMC Women’s Health. The study, entitled “Beyond Tradition: Investigating TruScreen’s Performance
Versus Pap Smear in Cervical Cancer Detection”
1
tested 507 women and was first published on Research
Square1 Link on 25 July 2024. Results showed that TruScreen demonstrated: High Sensitivity: TruScreen 83.3%,
compared to Pap Smear 66.7% / High Specificity: TruScreen 95%, compared to Pap Smear 98.2%
•April and May 2025 – TruScreen and the Baylor Foundation Eswatini agree on the validation and initial product
training for TruScreen to be used for a pilot program to screen women in Eswatini, formally Swaziland

TruScreen Outlook:
FY26 and beyond

37
FY25 Sales (Actual)FY26 Sales (Projection)
Projected +64% YOY increase with increased diversification of revenue
NZ$ 1.71m
NZ$ 2.8m
This slide contains forward-looking information and should be read in
conjunction with the important information on pages 2 – 4 of this presentation

38
TruScreen Expected Sales Increase FY26
Six key
provinces
targeted;
Expected sales
increase >15%
> NZ$ 1.75m
Public
Screening
Program to
resume;
Expected sales
> NZ$ 300k
Indonesia and
India sales
commence;
Expected sales
> NZ$ 300k
Dalton Bio IVD
HPV Test sales
to commence;
Expected sales
> NZ$ 200k
Ho Chi Minh
City Public
Screening
Program to
commence and
hospital sales
to increase;
Expected sales
> NZ$ 150k
Public
Screening to
commence;
Expected sales
> NZ$ 100k
Expected sales
> NZ$ 100k
NZ$ 2.8m
This slide contains forward-looking information and should be read in conjunction with the
important information on pages 2 – 4 of this presentation

39
Focus on key growth provinces (Shandong,
Jiangsu,, Hunan, Zhejiang, Guangdong,
Guangxi) - Total popn 496m
Market expansion to continue with
China the key focus
Strengthen vertical Asian market from
Indonesia through China, and capitalise on
Indian distribution network
Build on International NGO Recognition (WHO,
UNITAID, CHAI, COGA , CSCCP) to build
acceptance and remove barriers to sale
Strengthen China Distribution
Capability via Strategic Partnership
with Dalton Bio
Target Govt and NGO funded
programs in Zimbabwe, Vietnam,
Mexico and Uzbekistan
Growth Strategies

40
Developing strategic partnerships for
complementary woman’s health services
Focus on countries with limited or nil
cervical screening capability
Expand product portfolio to include Dalton
Bio HPV related IVD products DNA tests,
including HPV DNA tests and self sampling
Capitalise on global focus on AI
enabled cervical cancer technologies –
e.g. WHO
Reduce SUS and Device COGS and
increase margins
Growth Strategies (cont.)

TruScreen Options
Key Terms:

42
Attached Share Option
Subject to Shareholder approval by way of an ordinary resolution at a special meeting of TruScreen shareholders,
Eligible Shareholders who participate in the SPP or the Placement will also receive an unlisted option (“Share
Option”) with the following rights and liabilities:
(a) Rights and liabilities attaching to the Options: Each Share Option issued by the Company will entitle
its holder (“Optionholder”) to subscribe for one (1) fully paid ordinary share in the Company (“Share”) on
the following terms and conditions.
(b) Expiry Date:
i. The Share Options will expire at 7:00pm New Zealand Time on the date that is one (1) year from the
date of issue of the initial shares issued pursuant to the SPP or Placement (as applicable) (“Expiry
Date”).
ii.Any Share Options not validly exercised before the Expiry Date will automatically lapse on the
Expiry Date.
(c) Exercise Price: The amount payable upon exercise of each Share Option is A$[0.02] (NZ$[0.022]
(“Exercise Price”).
(d) Exercise multiples: The Share Options held by an Optionholder may be exercised in whole or in part. If
exercised in part, there is no minimum exercise multiple.

43
(e) Exercise Notice: An Optionholder may exercise their Share Options at any time before they lapse by
lodging with the Company:
i. a written notice of exercise of Share Options specifying the number of Share Options being
exercised (“Exercise Notice”); and
ii.electronic funds transfer for the Exercise Price for the number of Share Options being exercised.
(f) Effective exercise: The exercise of any Share Options is only effective on and from the later of:
i.the date of receipt by the Company of an Exercise Notice for those Share Options; and
ii.when the Company has received the full amount of the Exercise Price for those Share Options in
cleared funds.
(g) Timing of issue of Shares on exercise: The Company will issue to the Optionholder, on the last
Australasian Business Day of the calendar month following a valid exercise of Share Options in
accordance with paragraph (f) above, the number of Shares required under these terms and conditions to
be issued in respect of the number of Share Options validly exercised by the Optionholder. The Company
will take any necessary steps to ensure that, immediately after the Shares are issued, they are quoted on
the ASX or NZX.

44
(h) Shares issued on exercise: All Shares issued upon the exercise of any Share Options will upon
issue rank pari passu in all respects with other Shares.
(i)Share Options not transferable: The Share Options are not transferable.
(j) Quotation of Share Options: The Company will not apply for quotation of the Share Options on ASX
or NZX.
(k) Reorganisation of capital: If at any time the issued capital of the Company is reorganised, all
rights of an Optionholder are to be changed in a manner consistent with, and to the extent necessary
to comply with, the Listing Rules applying to reorganisations of capital at the time of the
reorganisation.

45
(l) Participation in new issues: There are no participation rights or entitlements inherent to the Share
Options and the Optionholders will not be entitled to participate in new issues of capital offered to
Shareholders during the currency of the Share Options (unless the relevant Share Options have been
validly exercised and the Optionholder has been entered in the register of members of the Company as
holding the Shares issued to it on exercise of those Share Options).
(m) No voting rights: The Share Options do not carry any voting rights.
(n) Change in exercise price: Subject to paragraph (k) above, an Option does not confer the right to a
change in exercise price or a change in the number of underlying securities over which the Option can
be exercised.
Terms capitalised but otherwise not defined in pages 42 – 44 of this Investor Presentation shall have the meaning given to them
in the SPP Booklet released to the market on or about the date of this Investor Presentation.

46
Contact us for more Information
Guy Robertson
Chief Financial Officer

M – +61 407 983 270
E – guyrobertson@truscreen.com
TruScreen
Suite 3.03 18 Orion Rd
Lane Cove West NSW 2066
Australia
www.truscreen.com
Martin Dillon
CEO
M - +61 449 115 065
E – martindillon@truscreen.com
TruScreen
Suite 3.03 18 Orion Rd
Lane Cove West NSW 2066
Australia
www.truscreen.com
References
*Women aged 15-64 years as detailed in the World Fact Book : https://www.cia.gov/the-world-factbook/